Drug class
The therapeutic class "Clostridioides (Clostridium) difficile Monoclonal Antibody" refers to targeted biological agents engineered to bind and neutralize the pathogenic exotoxins—principally toxin B (TcdB)—secreted by *Clostridioides difficile*. Read more about Clostridioides (Clostridium) difficile Monoclonal Antibody
1 drugs in this class 1 manufacturers
The therapeutic class "Clostridioides (Clostridium) difficile Monoclonal Antibody" refers to targeted biological agents engineered to bind and neutralize the pathogenic exotoxins—principally toxin B (TcdB)—secreted by *Clostridioides difficile*.
By providing passive immunity and neutralizing toxin activity, these agents inhibit toxin-mediated cellular damage and severe mucosal inflammation in the gastrointestinal tract.
Rather than functioning as bactericidal antibiotics to treat acute infection, drugs in this class are utilized as adjunctive passive immunotherapies administered alongside standard antibacterial regimens to reduce the incidence of recurrent *C.
difficile* infection and associated pseudomembranous colitis in high-risk patients.
The therapeutic class "Clostridioides (Clostridium) difficile Monoclonal Antibody" refers to targeted biological agents engineered to bind and neutralize the pathogenic exotoxins—principally toxin B (TcdB)—secreted by *Clostridioides difficile* By providing passive immunity and neutralizing toxin activity, these agents inhibit toxin-mediated cellular damage and severe mucosal inflammation in the gastrointestinal tract Rather than functioning as bactericidal antibiotics to treat acute infection, ...
The therapeutic class "Clostridioides (Clostridium) difficile Monoclonal Antibody" refers to targeted biological agents engineered to bind and neutralize the pathogenic exotoxins—principally toxin B (TcdB)—secreted by *Clostridioides difficile* By providing passive immunity and neutralizing toxin activity, these agents inhibit toxin-mediated cellular damage and severe mucosal inflammation in the gastrointestinal tract Rather than functioning as bactericidal antibiotics to treat acute infection, ...
By providing passive immunity and neutralizing toxin activity, these agents inhibit toxin-mediated cellular damage and severe mucosal inflammation in the gastrointestinal tract
Rather than functioning as bactericidal antibiotics to treat acute infection, drugs in this class are utilized as adjunctive passive immunotherapies administered alongside standard antibacterial regimens to reduce the incidence of recurrent *C. difficile* infection and associated pseudomembranous colitis in high-risk patients
Following a drug class requires a free Physicians Office Resource account.
